Oragenics (OGEN) Competitors $0.18 0.00 (-2.02%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.18 +0.00 (+1.71%) As of 04/17/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OGEN vs. IBIO, BIVI, CMMB, ELEV, BCTX, BFRG, CING, BCAB, MIRA, and MEShould you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include iBio (IBIO), BioVie (BIVI), Chemomab Therapeutics (CMMB), Elevation Oncology (ELEV), BriaCell Therapeutics (BCTX), Bullfrog AI (BFRG), Cingulate (CING), BioAtla (BCAB), MIRA Pharmaceuticals (MIRA), and 23andMe (ME). These companies are all part of the "pharmaceutical products" industry. Oragenics vs. iBio BioVie Chemomab Therapeutics Elevation Oncology BriaCell Therapeutics Bullfrog AI Cingulate BioAtla MIRA Pharmaceuticals 23andMe Oragenics (NYSE:OGEN) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk. Which has preferable earnings and valuation, OGEN or IBIO? Oragenics has higher earnings, but lower revenue than iBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOragenics$40K93.95-$20.66M-$1.70-0.10iBio$375K23.44-$24.91MN/AN/A Is OGEN or IBIO more profitable? iBio's return on equity of -73.15% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets OragenicsN/A -2,087.95% -486.56% iBio N/A -73.15%-45.51% Do insiders & institutionals have more ownership in OGEN or IBIO? 18.7% of Oragenics shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 10.1% of Oragenics shares are held by company insiders. Comparatively, 0.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in OGEN or IBIO? iBio received 3 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 37.50% of users gave iBio an outperform vote while only 0.00% of users gave Oragenics an outperform vote. CompanyUnderperformOutperformOragenicsOutperform VotesNo VotesUnderperform Votes51100.00% iBioOutperform Votes337.50% Underperform Votes562.50% Which has more risk & volatility, OGEN or IBIO? Oragenics has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, iBio has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Does the media prefer OGEN or IBIO? In the previous week, Oragenics' average media sentiment score of 0.00 equaled iBio'saverage media sentiment score. Company Overall Sentiment Oragenics Neutral iBio Neutral Do analysts prefer OGEN or IBIO? iBio has a consensus price target of $4.30, indicating a potential upside of 383.15%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Oragenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oragenics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00iBio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryiBio beats Oragenics on 9 of the 13 factors compared between the two stocks. Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGEN vs. The Competition Export to ExcelMetricOragenicsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.76M$6.44B$5.30B$18.41BDividend YieldN/A3.21%5.45%4.20%P/E Ratio-0.026.8921.8631.07Price / Sales93.95230.51380.5226.55Price / CashN/A65.6738.2617.53Price / Book0.295.936.454.30Net Income-$20.66M$142.99M$3.22B$1.02B1 Month Performance-31.26%-13.57%-9.71%-8.22%1 Year Performance-84.51%-8.90%11.52%1.66% Oragenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGENOragenicsN/A$0.18-2.0%N/A-84.8%$3.76M$40,000.00-0.025IBIOiBio1.0928 of 5 stars$1.51-53.1%$4.30+184.8%-49.7%$14.91M$375,000.000.00100High Trading VolumeBIVIBioVie1.3829 of 5 stars$0.80+3.2%$3.00+275.2%+72.2%$14.75MN/A-0.0810CMMBChemomab Therapeutics2.8582 of 5 stars$1.02-2.9%$9.00+782.4%+60.0%$14.65MN/A-1.0220Gap DownELEVElevation Oncology2.929 of 5 stars$0.25-1.8%$3.39+1,278.5%-90.4%$14.54MN/A-0.3040News CoverageGap UpBCTXBriaCell Therapeutics1.4122 of 5 stars$3.86-2.0%$32.00+729.0%-86.6%$14.32MN/A-0.298News CoverageGap DownBFRGBullfrog AI0.6181 of 5 stars$1.52+16.9%N/A-45.0%$14.31M$60,000.00-1.794Short Interest ↑News CoverageCINGCingulate2.0878 of 5 stars$3.74-1.1%$16.00+327.8%+381.8%$14.09MN/A-0.2620Short Interest ↑Negative NewsBCABBioAtla1.9587 of 5 stars$0.29+3.5%$6.00+1,968.3%-86.7%$14.03M$11M-0.1760Positive NewsGap UpMIRAMIRA Pharmaceuticals2.7162 of 5 stars$0.80-3.8%$14.00+1,643.9%+8.5%$13.50MN/A-1.432Short Interest ↓News CoverageGap DownME23andMe0.4181 of 5 stars$0.50-35.3%$9.40+1,787.6%-95.1%$13.36M$208.78M-0.03770Gap DownHigh Trading Volume Related Companies and Tools Related Companies iBio Competitors BioVie Competitors Chemomab Therapeutics Competitors Elevation Oncology Competitors BriaCell Therapeutics Competitors Bullfrog AI Competitors Cingulate Competitors BioAtla Competitors MIRA Pharmaceuticals Competitors 23andMe Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGEN) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OGEN Stock Free OGEN Stock Alerts